"Global Cancer Antibody Drug Conjugate Market, Price, Dosage and Clinical Trials Insight 2026" offers comprehensive clinical and non clinical insight on the recent trends and the opportunities that the market has been experiencing at a regional and at global level. The cancer antibody drug conjugate market has been witnessing tremendous growth and offers unexplored potential to pharmaceutical companies involved in development of anti cancer therapeutics market. This new drug class is widely accepted in the form of monotherapy as well as combinational therapy among the breast cancer, Acute Leukemia and Lymphoma patients. In addition to the various strategies that have been employed by the major key players of the market, the report also delivers information regarding the achievements, valuable highlights and all the progressive compilations that have been made in the market.
After the approval of first ADC i.e. Pfizer’s Mylotarg in year 2000, the antibody drug conjugates are continuously witnessing exponential growth and are emerging as most prominent therapeutic approach for the management of cancer. After the withdrawal of Mylotarg, two new antibody drug conjugates entered into the market, which took the antibody drug conjugates market to the next level. Further, the Mylotarg was also reintroduced into the market in 2017 and currently 9 cancer antibody drug conjugates are available in the market, which are continuously boosting the cancer antibody drug conjugates market.
The drugs launched under antibody drug conjugates class have been designed in a way such that they show promising targeting activity. The drugs incorporate antibody specificity as well as cell killing activity of cytotoxic agents that have been chemically conjugated. Other than the efficient targeting activity, the drugs under it have been prominent in showing various other clinical applications. With 9 antibody drug conjugates available in the market and all being tremendously successful, namely Lumoxiti, Polivy, Mylotarg, Besponsa, Kadcyla and Adcetris, this therapeutic method have been classified as a potent treatment in oncology.
An advantage that is associated with this class of therapeutics is that it has the ability to effectively identify the cells that are foreign or not healthy. In the present scenario, all the clinicians, non-clinicians and the patients are getting inclined towards it as it has overcome the challenge that were highlighted during other treatment procedure i.e. toxicity related issues. The current trend that the market states is that this novel therapeutic regimen has now become a part of mainstream oncology healthcare system and has achieved significant warmth in the oncology department all around the globe.
As per report findings, the cancer antibody drug conjugates will shown tremendous success in the upcoming years in both the research and market segments. The continuous success of the approved cancer antibody drug conjugates and presence of many new antibody drug conjugates in the clinical pipeline is indicating a very bright future for this market. The challenges for this market are very few, which can be easily prevail over in a short period of time and the driving factors such as unmet medical demand and high prevalence of cancer, are continuously boosting the market growth. We believe that in upcoming years, the antibody drug conjugates will occupy a dominant share in overall oncology market and it will emerge as most prominent cancer therapeutic segment.
1. Introduction to Antibody Drug Conjugates (ADCs)
1.1 Overview
1.2 Historical Development of ADCs
2. Evolution of Antibody Drug Conjugates
2.1 Advancements in ADCs
2.1.1 First Generation
2.1.2 Second-Generation
2.1.3 Third Generation
2.2 Components of ADCs
2.2.1 Monoclonal Antibodies (mAbs)
2.2.2 Linkers
2.2.3 Payloads
3. Antibody Drug Conjugates - Mechanism of Action
3.1 Antigen - Antibody Interaction
3.2 Release of Payload
3.3 Mechanism of Cytotoxicity
4. Need of Antibody Drug Conjugates
5. Role of ADCs in Cancer Management
5.1 Breast Cancer
5.2 Leukemia
5.3 Lymphoma
5.4 Other Cancers
6. Antibody Drug Conjugate Market Analysis
6.1 Overview
6.2 Current Market Scenario
6.3 ADCs Market Segmentation
6.3.1 Regional Segmentation
6.3.2 Segmentation By Products
7. Global – Cancer Antibody Drug Conjugate Market Insights
7.1 US
7.2 Europe
7.2.1 Germany
7.2.2 Belgium
7.2.3 France
7.2.4 United Kingdom
7.3 Japan
7.4 China
7.5 India
7.6 South Korea
8. Antibody Drug Conjugates - Availability, Dosage and Price Analysis
11. Global Cancer Drug Conjugates Clinical Pipeline By Company, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-0
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered
12. Marketed Cancer Drug Conjugates Clinical Insight
12.1 Adcetris
12.2 Mylotarg
12.3 Junovan/Mepact
12.4 Kadcyla
12.5 Besponsa
12.6 Zevalin/ Zevamab
12.7 LUMOXITI
12.8 OncoScint CR/OV
12.9 Enhertu
13. Global Cancer an Antibody Drug Conjugates Market Dynamics
13.1 Favorable Parameters
13.2 Challenges for Antibody Drug Conjugates Market
14. Antibody Drug Conjugates Market - Future Outlook
15. Competitive Landscape
15.1 AstraZeneca plc
15.2 Genentech
15.3 Roche
15.4 Takeda Pharmaceuticals
15.5 Pfizer
15.6 Oxford BioTherapeutics
15.7 Heidelberg Pharma
15.8 Synthon
15.9 Mersana Therapeutics
15.10 Progenics Pharmaceuticals
15.11 Astellas Pharma
15.12 Bristol Mayer Squibb
15.13 Seattle Genetics
15.14 Immunogen
15.15 Celldex Therapeutics
Figure 1-1: Historical Development of Antibody-Drug Conjugate
Figure 1-2: Approval History of Commercially Available Antibody-Drug Conjugates
Figure 2-1: Classification of Antibody-Drug Conjugates
Figure 2-2: Components of Antibody-Drug Conjugates
Figure 2-3: Antigen Expression Analyzing Techniques used in Development of ADCs
Figure 2-4: Isotypes of Monoclonal Antibodies used in ADC Development
Figure 2-5: Classification of Linkers
Figure 2-6: Types of Cleavable Linkers
Figure 2-7: Non-Cleavable Linker Used in ADCs Development
Figure 2-8: Cytotoxic Drugs Used in Antibody Drug Conjugates
Figure 3-1: General Mechanism of Antibody Drug Conjugates against Cancer
Figure 3-2: ADCs - Antigen-Antibody Interaction in Normal and Cancerous Cells
Figure 3-3: Releasing Mechanism of Payloads
Figure 3-4: Mechanism of Cytotoxicity via Alkylating Agents
Figure 3-5: Mechanism of Toxicity via Tubulin Inhibitors
Figure 4 1: Therapeutic Index – Antibody Drug Conjugate vs. Cytotoxic Drug
Figure 6-1: Global - Number of Breast Cancer Cases and HER2+ Breast Cancer Cases (Million), 2018
Figure 6-2: Global - Number of HER2+ Breast Cancer Cases vs. Other Breast Cancer (%), 2018
Figure 6-3: Survival Rate at Different Stages of Breast Cancer (%)
Figure 6-4: Global – Newly Diagnosed ALL Cases and Deaths, 2019
Figure 6-5: Global – Newly Diagnosed AML Cases and Deaths, 2019
Figure 6-6: Global – Newly Diagnosed Non-Hodgkin Lymphoma Cases and Deaths, 2019
Figure 6-7: Global – Newly Diagnosed AML Cases and Deaths, 2019
Figure 6-8: Global – Cancer Drug Market – Total vs. ADCs (US$ Billion), 2019
Figure 6-9: Global – Cancer Drug Market – ADCs vs. Others (US$ Billion), 2019
Figure 6-10: Global – Antibody Drug Conjugates Market Size (US$ Billion), 2018 and 2019
Figure 6-11: Global – Antibody Drug Conjugates Market Opportunity (US$ Billion), 2019 - 2026
Figure 6-12: Global – Antibody Drug Conjugate Regional Market Share (%), 2019
Figure 6-13: Global – Antibody Drug Conjugate Market Size – Total vs. Kadcyla (US$ Billion), 2019
Figure 6-14: Global – Antibody Drug Conjugate Market Share (%) – Kadcyla vs. Others, 2019
Figure 6-15: Global – Antibody Drug Conjugate Market Share (%) – Adcetris vs. Others, 2019
Figure 6-16: Global – Antibody Drug Conjugate Market Segmnetation by Product (%), 2019
Figure 7-1: US- Cancer Statistics (Million), 2018
Figure 7-2: US – Clinical Trial Status for Cancer Antibody Drug Conjugates, 2020
Figure 7-3: Europe – Cancer Statistics (Million), 2018
Figure 7-4: Germany – Cancer Statistics (Million), 2018
Figure 7-5: Belgium – Cancer Statistics, 2018
Figure 7-6: France – Cancer Statistics (Million), 2018
Figure 7-7: United Kingdom – Cancer Statistics (US$ Million), 2018
Figure 7-8: Japan – Cancer Death Statistics (%), 2018
Figure 7-9: Japan – Clinical Trial Status, 2020
Figure 7-10: Japan – Amount Paid by Company vs. Insured (%),
Figure 7-11: China – Cancer Statistics (Million), 2018
Figure 7-12: China – Clinical Trials for Cancer Antibody Drug Conjugate Drugs, 2020
Figure 7-13: China – Reimbursement Status Company vs. Insured (%), 2020
Figure 7-14: India – Cancer Statistics (Million), 2018
Figure 7-15: India – Research and Development Spending by Pharmaceutical Companies (US$ Million), 2018
Figure 7-16: South Korea – Cancer Statistics (Million), 2018
Figure 7-17: South Korea – Clinical Trial Status, 2018
Figure 8-1: Commercially Available Antibody Drug Conjugates
Figure 8-2: Mylotarg – FDA Approval, Withdrawal and Re-Approval Year
Figure 8-3: Mylotarg – Number of Induction Cycle and Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 8-4: Mylotarg – Cost of Induction Cycle, Consolidation Cycles and Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), December’2019
Figure 8-5: Mylotarg – Recommended Number of Induction and Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML, December’2019
Figure 8-6: Mylotarg – Length of Induction and Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days), December’2019
Figure 8-7: Mylotarg – Recommended Dose of Initial Dose and Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2), December’2019
Figure 8-8: Mylotarg – Cost of Induction Phase and Continuation Phase and Full Treatment Cost of CD-33 positive AML (US$), December’2019
Figure 8-9: Mylotarg – Cost of Single Dose and Full Treatment Cost of Relapsed and Refractory CD33 Positive AML, December’2019
Figure 8-10: Adcetris – Patent Issue and Expiration Year
Figure 8-11: Adcetris – Duration of Single Treatment Cycle and Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks), December’2019
Figure 8-12: Adcetris – Maximum Cost of Single Treatment Cycle and Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), December’2019
Figure 8-13: Adcetris – Duration of Single Treatment Cycle and Full Treatment of Classical Hodgkin Lymphoma (Weeks), December’2019
Figure 8-14: Adcetris – Maximum Cost of Single Treatment Cycle and Full Treatment of Classical Hodgkin Lymphoma (US$), December’2019
Figure 8-15: Adcetris – Maximum Cost of Single Treatment Cycle and Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), December’2019
Figure 8-16: Adcetris – Duration of Single Treatment Cycle and Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks), December’2019
Figure 8-17: Adcetris – Maximum Cost of Single Treatment Cycle and Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), December’2019
Figure 8-18: Kadcyla – FDA Approval Year for Late Stage and Early Stage HER2+ Breast Cancer
Figure 8-19: Kadcyla – Price for Single Unit of 100mg and 150mg Intravenous Powder for Injection (US$), December’2019
Figure 8-20: Kadcyla - Duration of Single Treatment Cycle and Full Treatment of Early Stage HER2+ Breast Cancer (Weeks), December’2019
Figure 8-21: Kadcyla – Average Cost of Single Treatment Cycle and Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), December’2019
Figure 8-22: Kadcyla – Recommended Dose After 1st and 2nd Dose Reduction (mg/m2), December’2019
Figure 8-23: Besponsa – Orphan Market Exclusivity Issue and Expiration Year
Figure 8-24: Besponsa – Duration of Initial Treatment Cycle and Subsequent Cycles (Days), December’2019
Figure 8-25; Besponsa – Recommended Dose for 1st, 8th and 15th Day of Initial Treatment Cycle (mg/m2), December’2019
Figure 8-26: Besponsa – Cost of Single Unit and Full Cost of Initial Treatment Cycle (US$), December’2019
Figure 8-27: Besponsa – Cost of Single Unit and Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), December’2019
Figure 8-28: Besponsa – Cost of Single Unit and Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), December’2019
Figure 8-29: Besponsa – Duration of Treatment of ALL – After and Without HSCT (Weeks), December’2019
Figure 8-30: Besponsa – Full Treatment Cost of ALL Patients with and Without Complete Remission after HSCT (US$), December’2019
Figure 8-31: Lumoxiti – Year of Orphan Designation, FDA Approval and Patent Expiration
Figure 8-32: Lumoxiti – Duration of Single Treatment Cycle and Full Treatment (Weeks), December’2019
Figure 8-33: Lumoxitin – Cost of Single Dose, Single Treatment Cycle and Full Treatment of Hairy Cell Leukemia (US$), 2019
Figure 8-34: Polivy – Patent Issue and Expiration Year
Figure 8-35: Polivy - Duration of Single Treatment Cycle and Full Treatment (Weeks), December’2019
Figure 8-36: Polivy – Cost of Single Dose, Single Treatment Cycle and Full Treatment of Hairy Cell Leukemia (US$), 2019
Figure 8-37: Bendamustine – Price for Single Unit and 4ml of 25mg/ml Bendamustine Intravenous Solution for Injection (US$), December’2019
Figure 8-38: Rituximab – Price for 1ml and 10ml of 10mg/ml Rituximab Intravenous Solution for Injection (US$), December’2019
Figure 8-39: Enhertu – FDA Priority Review and Approval Year
